This is evident in several other drug candidates (i.e., Inclacumab, a monoclonal antibody against P-selectin, was dropped for cardiovascular diseases treatment and is now in trials for the treatment of sickle cell disease [40]). This evidence concerns the gene SELP and sickle cell disease.